Performed using FFPE samples, LDTPP can quantify levels of protein biomarkers in tissue subregions of interest collected via laser microdissection. Protein is extracted, fragmented, labelled and quantified by mass spectrometry. Bioinformatic analysis of the mass spec data integrated with microarray data identifies signalling pathways that are affected by a treatment.
We have successfully measured protein biomarker changes (relative to control) in laser dissected liver samples (FFPE sections) treated with a non genotoxic carcinogen (results presented at the 55th Annual meeting of the Society of Toxicology, New Orleans 2016)
Proteins were extracted from FFPE sections and digested prior to performing LC MS/MS using an Orbitrap mass spectrometer.
Our method integrates proteomics data with transcriptomic expression datasets to derive composite mode of action biomarkers that more accurately reflect efficacy/toxicity response to drugs compared to non-composite biomarkers (RNA profiling alone or protein profiling alone.)
This proprietary approach allows for precise quantitation of protein biomarkers located to tissue subregions, providing drug outcome ranking parameters which are linked to complex mode of action insights.
Laser dissection targeted proteomic profiling (LDTTP) offers a unique capability for linking effects on signaling pathways with functional outcomes, facilitating smarter compound selection and de-risking; for more details please see our LDTPP flyer.
on an interactive, step by step basis. Collaborations can begin with pilot projects which can then be scaled up to larger research programs, according to your requirements.
